Validity and Limits of the Rebound Tonometer (ICare®): Clinical Study

Scuderi, Gianluca; Cascone, Nikhil; Regine, Federico; Perdicchi, Andrea; Cerulli, Angelica; Recupero, Santi Maria

doi:10.5301/ejo.2010.3712

Cited by 55 publications

(31 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Nevertheless, ICRBT overestimated IOP by 2.3 mmHg. This was similar to most of the previous studies, which reported overestimations from 0.2 to 3.4 mmHg [7][8][9][10][11][12][13][14][15][16][17][18][19][20]. Recently, Vasanthan Mutuvelou et al [30] showed that central ICare measurements overestimated IOP by 2 mmHg and that peripheral measurements underestimated IOP by approximately 1.4-2 mmHg.…”

Section: Discussionsupporting

confidence: 90%

“…Several studies have shown that the Icare tonometer provided good results in terms of ease of use, precision, and reproducibility of its measurements. It has been also shown to correlate well with GAT, even in the hands of inexperienced tonometrists [7][8][9][10][11][12][13][14][15][16][17][18][19][20]. Recently a version of the Icare tonometer (Icare ONE) for home measurement of IOP by patients became commercially available [21].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of the Icare-ONE rebound tonometer as a self-measuring intraocular pressure device in normal subjects

Halkiadakis

Stratos

Stergiopoulos

et al. 2012

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Introductionmentioning

confidence: 99%

Evaluation of the Icare-ONE rebound tonometer as a self-measuring intraocular pressure device in normal subjects

Halkiadakis

Stratos

Stergiopoulos

et al. 2012

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

show abstract

“…The same examiner performed all of the IOP measurements for each patient. The reliability and reproducibility of the IOP data obtained using the ICare tonometer were verified previously [26][27][28][29][30][31].…”

Section: Outcome Measuresmentioning

confidence: 60%

Immediate changes in intraocular pressure after clear corneal micro-incision versus small-incision cataract surgery

2014

View full text Add to dashboard Cite

show abstract

“…At the slit-lamp examination, the anterior segment was normal and with no signs of any ocular inflammation. His intraocular pressure (IOP) at Goldmann tonometry and iCare [4] was 17 mm Hg.…”

Section: Case Presentationmentioning

confidence: 99%

Intravitreal Injection of Dexamethasone Implant and Ranibizumab in Cystoid Macular Edema in the Course of Irvine-Gass Syndrome

Fenicia

Balestrieri

Perdicchi

et al. 2014

Case Rep Ophthalmol

Self Cite

View full text Add to dashboard Cite

Purpose: To evaluate the efficacy of 2 dexamethasone intravitreal implants and 1 ranibizumab intravitreal injection after a bilateral postoperative complication of cataract surgery as pseudophakic cystoid macular edema. Patients and Methods: A 70-year-old male patient with systemic hypertension developed a progressive cystoid macular edema (CME) in both eyes starting between 10 and 20 days after cataract surgery. Two intravitreal dexamethasone implants and 1 ranibizumab injection were administered; first in the right eye (RE) and then in the left eye (LE). The patient was checked for 1 whole week and then once a month for 5 months after the injections. Results: One month after the first dexamethasone implant in his RE, the spectral domain optical coherence tomography (SD-OCT) showed a progressive reduction of the foveal thickness until a complete resolution of the CME occurred, which was associated with an improvement of visual acuity. After 3 months, the SD-OCT showed a relapse of the CME, which was then treated with 1 injection of ranibizumab. One month after this injection, there was a complete resolution of the CME. A new CME in his RE was diagnosed 2 months after the last ranibizumab injection; it was treated with a new dexamethasone implant. A complete resolution of the CME was obtained; a normal foveal profile was still present 5 months after the last injection, and the best-corrected visual acuity was 20/20. His LE developed a CME 40 days after surgery. One intravitreal injection of ranibizumab was first administered in his LE, with a complete resolution of the CME at SD-OCT 2 weeks later. As observed in his RE, 40 days after the ranibizumab injection, there was a relapse of the CME that was treated with 1 intravitreal injection of dexamethasone implant. Five months later, the patient showed a worsening of the CME, but it was completely resolved with a second dexamethasone injection. After 3 months, the foveal thickness was back to normal with a BCVA of 20/20. Conclusion: Treatment with dexamethasone implants (Ozurdex®) and ranibizumab injections (Lucentis®) induced a progressive reduction of our patient's CME after cataract surgery (Irvine-Gass syndrome) until a complete normal foveal thickness was restored and his visual function was improved despite the order of injections.

show abstract

Validity and Limits of the Rebound Tonometer (ICare®): Clinical Study

Cited by 55 publications

References 25 publications

Evaluation of the Icare-ONE rebound tonometer as a self-measuring intraocular pressure device in normal subjects

Evaluation of the Icare-ONE rebound tonometer as a self-measuring intraocular pressure device in normal subjects

Immediate changes in intraocular pressure after clear corneal micro-incision versus small-incision cataract surgery

Intravitreal Injection of Dexamethasone Implant and Ranibizumab in Cystoid Macular Edema in the Course of Irvine-Gass Syndrome

Contact Info

Product

Resources

About